Project Grant HT94252510286
Award Date
6/1/25
Completion Date
8/31/25
Dollars Obligated
$299K
Federal Agency
Defense Health Agency
Awardee
Microquin LTD (UVZ4XT6GKZ36)
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Cambridge, MA 02139, USA
Similar Awards
The Department of the Army Medical Command awarded a $248,250 Project Grant to Microquin LTD on June 1, 2022 to support the development of a first-in-class therapeutic to treat epithelial ovarian cancer. The work will be performed in Cambridge, MA from June 1, 2022 through May 31, 2023. The grant is being funded through the Military Medical Research and Development program (CFDA 12.420), which supports basic, applied, and advanced biomedical research with the goals of transforming military and...
The Defense Health Agency has awarded a $968,400 Project Grant to Mayo Clinic to develop a personalized approach to treating drug-resistant ovarian cancer. The grant, which began on June 1, 2024, and will run through May 31, 2028, is funded under the Military Medical Research and Development program (CFDA 12.420). This program supports biomedical research to improve the health and care of military service members, veterans, and their families. Through this award, Mayo Clinic will leverage its...
This Project Grant award of $420,000.00 was provided by the Defense Health Agency, under the Military Medical Research and Development program (CFDA 12.420), to Kuda Therapeutics, Inc., a woman-owned small business. The funding supports basic, translational, and clinical research to investigate ferroptosis as a therapeutic strategy for clear cell ovarian cancer, with the goal of improving health outcomes for military service members, veterans, and their families. The research will be conducted...
The Department of Defense, through the Military Medical Research and Development program (CFDA 12.420), awarded a $1,128,000 Project Grant to The Institute For Cancer Research to conduct research on "Restoring PALB2 Function as a Mechanism of PARP1 Resistance in BRCA1-Mutant EOC". The award, with a performance period from July 1, 2024 to June 30, 2028, supports innovative scientific research aimed at improving health outcomes for military service members, veterans, and the broader...
The U.S. Department of Defense's Defense Health Agency awarded a 3-year, $954,000 Project Grant to the Massachusetts Institute of Technology (MIT) under the Military Medical Research and Development (CFDA 12.420) federal grant program. The grant, titled "TUMOR-TARGETED NANOCARRIERS FOR EFFECTIVE IMMUNOMODULATION OF OVARIAN CANCER," supports advanced biomedical research focused on developing innovative tumor-targeted nanocarriers for effective immunomodulation of ovarian cancer. This...
The Defense Health Agency awarded a $778,092 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to the Dana-Farber Cancer Institute, Inc. (DFCI) for the purpose of "ADVANCING PRECLINICAL STUDIES OF DUAL-TARGETED FINE-TUNED IMMUNE-RESTORING (DFIR) CAR-T CELL THERAPY TO ACHIEVE CURES OF HIGH-GRADE SEROUS OVARIAN CANCER." The project aims to conduct preclinical studies on a novel dual-targeted CAR-T cell therapy approach to treat high-grade serous...
This Project Grant from the Defense Health Agency provides $494,811 to the University of Cambridge under the Military Medical Research and Development program (CFDA 12.420) from April 1, 2023 to March 31, 2026. The grant funds research to elucidate and target clonal lineages influencing resistance to therapy in distinct mutational subtypes of high-grade ovarian serous carcinoma. The Military Medical Research and Development program supports basic, applied, and advanced biomedical research to...
The University of Pittsburgh was awarded a $954,000 Project Grant from the Defense Health Agency under the Military Medical Research and Development federal grant program (CFDA 12.420). The grant will support research from May 2023 to May 2026 aimed at epigenetic reprogramming to target senescent ovarian cancer cells and overcome therapeutic resistance. The Military Medical Research and Development program supports basic, applied, and advanced biomedical research to transform military and public...
The federal Project Grant award of $1,214,375.00 from the Defense Health Agency, under the Military Medical Research and Development program (CFDA 12.420), is funding a research project led by Yale University. The project is investigating the use of decoy-resistant IL-18 and immune checkpoint inhibitors in preclinical murine and ex vivo patient-derived models of renal cell carcinoma. The award began on September 15, 2024 and is set to conclude on September 14, 2028. The Military Medical Research...
The Department of Defense's Defense Health Agency awarded a $999,300 Project Grant to Microquin LTD under the Military Medical Research and Development program (CFDA 12.420). The purpose of this 2-year grant, with a period of performance from September 30, 2023 to September 29, 2025, is to support Microquin's efforts to develop new chemical entities for treating traumatic brain injury. Microquin LTD is a biotechnology company that specializes in innovative medical solutions, including gene...